Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Company Overview - Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) [2] - Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials, demonstrating broad franchise potential [2] - The company has operations in San Diego and is leveraging its extensive experience to advance research on additional opportunities for azenosertib outside PROC [2] Upcoming Events - Members of the management team will participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA on March 3, 2025, at 11:50 a.m. ET [4] - The company will also participate in the Leerink Global Healthcare Conference in Miami, FL on March 10, 2025, at 9:20 a.m. ET [4] - Access to live webcasts of these events will be available on the company's website under the "Events & Presentations" section [1]